Cholera toxin (CT) was shown to bind to immobilized Ni 2⍣ ion. The affinity of CT for the complex required the presence of the Ni 2⍣ ion, since CT was unable to bind in its absence. Binding was mediated by the B-subunit (CTB) as both CT and CTB bound to the resin, but not the Asubunit (CTA). Binding was reversible in the presence of imidazole and suggested that the affinity of CT for the Ni 2⍣ ion was mediated by His residues. The heat-labile enterotoxin of Escherichia coli (LT), which is closely related to CT, was unable to bind to the Ni 2⍣ ion. Comparison of amino acid sequences revealed the presence of three His residues in CT (positions 13, 57 and 94), but only one in LT (position 57). To confirm that the residues at positions 13 and 94 of CTB were responsible for the binding, they were changed to residues found in LTB. Changing His13→Arg completely abrogated the ability of CTB to bind to Ni 2⍣ ion. In contrast, the mutation of His 94→Asn reduced, but did not abrogate, the ability of CTB to bind to Ni 2⍣ ion. Based on calculated interatomic distances, it is unlikely that His13 and His94 are part of the same complex. There appear to be two separate binding sites, with the principal site involving His13 and a much weaker site involving His94. This latter site can only participate in binding if the complex involving His13 has formed.
Introduction
Cholera toxin (CT) is composed of two subunits: a toxigenic A subunit (CTA) and five copies of the receptor binding B subunit (CTB). The latter mediates binding of CTA to the surface of eukaryotic cells via its interaction with the monosialoganglioside GM1 (Spangler, 1996) . The type I heat-labile enterotoxin of Escherichia coli (LT) is closely related to CT. It has an identical subunit structure and function and shares 80% amino acid homology with CT (Spangler, 1996) . Although LT is very similar to CT in structure and function, it binds to a broader array of ligands than CT, including glycolipids (Fukuta et al., 1988) and glycoproteins (Griffiths et al., 1986) .
The 3-D crystal structure has been determined for both CT (Zhang et al., 1995a) and LT (Sixma et al., 1991) . In addition, the crystal structure of CTB complexed with the GM1-pentasaccharide has also been determined (Merritt et al., 1994) . The crystal structure of this complex has revealed all interactions between the GM1 head group and the receptor binding site of CTB without any indication of the presence of a divalent ion binding site (Zhang et al., 1995b) . Also, no biochemical evidence exists indicating that cations mediate ganglioside binding. However, some of the receptors for these enterotoxins have only recently been identified (Karlsson et al., 1996) . Hence it is possible that there are additional receptors for CT and LT that are still unknown.
In the course of our work on developing CT for use as a mucosal adjuvant (Dertzbaugh and Elson, 1993a) , we have discovered that CT will bind to the Ni 2ϩ ion. A review of the literature indicated that this observation has not been reported previously and for this reason we have examined this property more closely. In this paper, we describe the results of this study, including the mechanism of binding and the amino acid residues that are critical for Ni 2ϩ binding to occur.
Materials and methods

Proteins and reagents
Cholera toxin (CT), the A subunit (CTA) and biotinylated CTB were purchased from List Biological Laboratories (Campbell, CA) and were purified from Vibrio cholerae Inaba strain 569B. Recombinant CTB was derived from the El Tor strain 62746 and was expressed and purified as described previously (Dertzbaugh and Elson, 1993b) . Purified type I human E.coli heat-labile enterotoxin (LT-h) was derived from strain Hc22/TP235km and was purchased from Berna Products (Coral Gables, FL). Sepharose CL-6B, composed of highly cross-linked agarose, was purchased from Pharmacia (Piscataway, NJ). Ni-NTA coupled to Sepharose CL-6B resin and Ni-NTA-coated ELISA plates were purchased from Qiagen (Chatsworth, CA).
Mutagenesis of CTB
Plasmid pCVD002, encoding the CT genes of V.cholerae El Tor strain 62746, was used as the template DNA for oligonucleotide-directed PCR mutagenesis of the CTB gene (Lockman and Kaper, 1983) . Oligonucleotides encoding the missense mutations His13→Arg13 (CAC→CGG) or His94→-Asn94 (CAT→AAT) were used as mutagenic primers. Each mutagenic oligonucleotide was combined with a non-mutagenic oligonucleotide to form a pair of flanking primers to modify the PCR-amplified template DNA. A double mutant incorporating both the R13 and N94 codon changes was also constructed by employing both mutagenic oligonucleotides as flanking primers in the PCR. Amplification was performed using Vent polymerase (New England Biolabs, Beverly, MA). The reaction mixture was prepared according to the manufacturer's directions and then subjected to 25 cycles of the temperature sequence 94°C for 1 min, 43°C for 1 min and 72°C for 1 min. The PCR-amplified product was directionally cloned into the expression vector pMTD107 as an EcoRI-BamHI fragment. Plasmid pMTD107 was derived from pET-8c (Studier et al., 1990) and includes a cassette encoding the ompA leader sequence (Ghrayeb et al., 1984) . In-frame insertion of a gene downstream of this sequence will result in expression of a fusion protein containing the OmpA leader peptide on its Nterminal end. Transformation of pMTD107 into the lysogenic E.coli strain HMS174(DE3) permits IPTG-inducible expression of protein from the T7 promoter (Studier et al., 1990) . Induced lysates were screened for expression of CTB by a sandwich ELISA, using goat anti-CTB (Calbiochem, La Jolla, CA) as the capture reagent and rabbit anti-CT (Sigma) as the primary antibody.
Expression and harvest of CTB mutants E.coli strains expressing mutant CTB were grown and induced as described previously (Dertzbaugh and Elson, 1993b) . A whole cell lysate was prepared by suspension of the cell pellet in a 1/10 culture volume of lysis buffer (20% sucrose, 50 mM Tris, 50 mM EDTA, pH 8.0) containing 1 mg/ml lysozyme. The suspension was incubated for 30 min at 37°C and then diluted to one culture volume with distilled water prior to being subjected to two cycles of rapid freeze-thaw. The lysate was clarified by centrifugation at 20 000 g for 20 min at 4°C. Mutant CTB protein was isolated from the lysate by fractional 20-60% (NH 4 ) 2 SO 4 precipitation. This material was used for all of the resin binding studies. For use in the competitive assays, the protein preparations were extensively purified. Briefly, (NH 4 ) 2 SO 4 precipitates containing mutant CTB were dialyzed in imidazole buffer (20 mM imidazole, 20 mM NaCl, pH 7.0) and then eluted from a MonoQ HR10/30 anionexchange column (Pharmacia) using a 0-250 mM NaCl gradient. Fractions containing protein were pooled and concentrated by ultrafiltration using an Amicon YM3 membrane (Amicon, Beverly, MA). The concentrated protein was eluted from a Superdex 75 HR26/60 gel filtration column (Pharmacia) equilibrated in TEAN buffer (50 mM Tris, 1 mM EDTA, 200 mM NaCl, 3 mM NaN 3 , pH 7.5). Fractions containing protein were pooled and adjusted to a final concentration of 1.0 mg/ml based on their absorbance at 280 nm. The purity of the CTB proteins was determined by Coomassie brilliant blue staining of samples separated by SDS-PAGE to be Ͼ90% (data not shown).
Reduction and alkylation of CTB Purified recombinant CTB was dialyzed against 50 mM Tris, pH 8.0, and then degassed in nitrogen for 20 min. Sodium dodecyl sulfate (SDS) and 2-mercaptoethanol (2-ME) were added to final concentrations of 1% and 0.2 M, respectively, and the solution was incubated at 37°C for 4 h. Reduced sulfhydryl groups on CTB were alkylated by the addition of a 10-fold molar excess of iodoacetic acid (IAA). Alkylation proceeded for 1 h at 25°C. SDS was removed from the suspension by passing it through a column containing Extract-D-Gel resin (Pierce, Rockford, IL) equilibrated in 50 mM Tris, pH 8.0. The suspension was dialyzed exhaustively against TBS, pH 7.5, and then stored at 4°C before use.
Resin binding studies
Protein samples precipitated with (NH 4 ) 2 SO 4 were extensively dialyzed against several changes of Tris-buffered saline (TBS) (20 mM Tris, 100 mM NaCl, pH 8.0) prior to addition to the resin. To prepare NTA-Sepharose devoid of the Ni 2ϩ ion, the Ni-NTA-Sepharose was washed with several changes of EDTA buffer (100 mM EDTA, 20 mM Tris, 100 mM NaCl, pH 8.0). The Ni-NTA-Sepharose, NTA-Sepharose and Sepharose CL-6B resins were each equilibrated with wash buffer prior to addition of the protein samples. The samples were gently mixed for 15 min with 400 µl of a 50% slurry of resin. Each Fig. 1 . Specificity of cholera toxin (CT) and its subunits for the Ni-NTA resin. Purified samples of CT, the A-subunit (CTA) and the B-subunit CTB) were evaluated for their ability to bind to the Ni-NTA resin. Protein was eluted using 50 mM imidazole. Tightly bound protein was eluted using 100 mM EDTA. A sample from each step was separated by SDS-PAGE on a 20% gel and the gel was stained with Coomassie brilliant blue to visualize protein. The positions of CTA and CTB are indicated by arrows on the right. Molecular mass markers (in kDa ϭ are shown on the left. Lanes: 1 ϭ CT, pre-resin; 2 ϭ CT, unbound; 3 ϭ CT, imidazole; 4 ϭ CT, EDTA; 5 ϭ CTA, pre-resin; 6 ϭ CTA, unbound; 7 ϭ CTA, imidazole; 8 ϭ CTA, EDTA; 9 ϭ CTB, pre-resin; 10 ϭ CTB, unbound; 11 ϭ CTB, imidazole; 12 ϭ CTB, EDTA.
suspension was centrifuged briefly to pellet the resin and the supernate was analyzed for the presence of unbound protein.
The resin was washed six times with 1 ml of TBS and bound protein was eluted from the resin by stepwise batch elution with increasing concentrations of imidazole in TBS. The suspension was gently mixed for 5 min with each concentration of imidazole to facilitate elution. As a final step, the resin was washed with 1 ml of EDTA buffer in order to remove any tightly bound protein. Samples were separated by SDS-PAGE and stained with Coomassie brilliant blue to visualize CTB. Competitive Ni-NTA ELISA Biotinylated CTB, diluted to a concentration of 500 ng/ml in TBS, pH 8.0, containing 10 mM NiSO 4 (TBSN), was added to each well of a preblocked uncoated polyvinyl microtiter plate. As a negative control, one set of wells did not receive any biotinylated CTB. Each competitor was initially diluted to a concentration of 1.72 µM in TBSN and then serially diluted 2-fold. Each dilution was performed in quadruplicate. As a positive control, one set of wells did not receive any competitor. The contents of each well were transferred into identical wells of a 96-well plate precoated with Ni-NTA (Qiagen) and the plate was incubated overnight at 4°C. Phosphatase-labeled streptavidin (KPL) diluted in TBS ϩ 1% bovine serum albumin (BSA; Sigma) was used as the secondary reagent. The absorbance at 405 nm (A 405 ) was determined for each well using p-nitrophenyl phosphate as the substrate. Crystal structure analysis Bond distances between atoms were calculated based on the coordinates deposited in the Brookhaven Protein Data Bank (PDB Id: 1FGH) (Zhang et al., 1995b) . The program RasMol (version 2.6 beta) was used to identify amino acid residues and to calculate bond distances (Sayle and Milner-White, 1995) .
Results
Subunit affinity and binding specificity of CTB
Purified samples of cholera toxin (CT), the A subunit (CTA) and the B subunit (CTB) were evaluated for their ability to bind to the Ni-NTA agarose resin. As shown in Figure 1, CT Fig. 2 . Specificity of cholera toxin B subunit (CTB) for the Ni 2ϩ ion. The affinities of a partially purified sample of recombinant CTB for Sepharose CL-6B, NTA-Sepharose and Ni-NTA-Sepharose were compared. CTB was mixed with equal amounts of each resin and Ni 2ϩ -bound protein was eluted with 50 mM imidazole. Tightly bound protein was eluted by washing the resin with 100 mM EDTA. The washes from each step were pooled, concentrated and adjusted to the same final volume. A sample of each wash was separated by SDS-PAGE on a 20% gel and total protein was visualized by Coomassie brilliant blue staining. The position of CTB is indicated by the arrow on the right. Molecular mass markers (in kDa) are shown on the left. Lanes: 1 ϭ CTB, pre-resin; 2 ϭ CL-6B, unbound; 3 ϭ CL-6B, imidazole; 4 ϭ CL-6B, EDTA; 5 ϭ NTA, unbound; 6 ϭ NTA, imidazole; 7 ϭ NTA, EDTA; 8 ϭ Ni-NTA, unbound; 9 ϭ Ni-NTA, imidazole; 10 ϭ Ni-NTA, EDTA.
and CTB were both able to bind to the Ni-NTA resin with high affinity. Trace amounts of CTA were detected in the imidazole wash, but at very low levels, compared with the pre-resin sample. In order to determine what component of the gel matrix mediated binding, purified samples of CTB were mixed with the following resins: Sepharose CL-6B, NTASepharose and Ni-NTA-Sepharose. By using a combination of these resins, it was possible to determine whether CTB was binding directly to the Sepharose-based bead, the NTA spacer arm or the Ni 2ϩ ion. Figure 2 shows that the ability of CTB to bind to the resin is clearly dependent on the presence of the Ni 2ϩ ion. CTB did not bind to the Sepharose CL-6B or to the NTA spacer arm. Inability of LT or denatured CTB to bind to the resin A purified sample of of E.coli heat-labile enterotoxin (LT) was examined for its ability to bind to the Ni-NTA resin. As shown in Figure 3 , the affinity of LT for the Ni-NTA resin was very poor compared with CT. In order to determine whether there was a structural requirement for CTB to bind to the resin, a sample of the protein was reduced and alkylated to eliminate disulfide bond formation. Reduction has been shown previously to eliminate the ability of CTB to bind to GM1 ganglioside (Ludwig et al., 1985) . An ELISA based on the ability of CTB to bind to GM1 confirmed that the reduced form of CTB retained only 0.6% of its original binding activity (data not shown). As Figure 4 illustrates, the reduced form of CTB was unable to bind to the resin, demonstrating that there is a conformational requirement for CTB to bind to the Ni 2ϩ ion.
Affinity of CTB mutants for Ni 2ϩ ion
The ability of CTB to be eluted from the Ni-NTA agarose by imidazole suggested that His residues may be involved. To test this hypothesis, PCR-mutagenized versions of the CTB gene were constructed as follows: His13→Arg (R13), His94→- Fig. 3 . Inability of heat-labile enterotoxin of E.coli (LT) to bind to the Ni-NTA resin. A purified sample of LT was examined for its ability to bind to Ni-NTA-Sepharose. Protein was bound and eluted from the resin as described as in Figure 1 . A sample from each wash was separated by SDS-PAGE on a 20% gel and total protein was visualized by Coomassie brilliant blue staining. The positions of LTA and LTB are indicated by the arrows on the right. Molecular mass markers (in kDa) are shown on the left. Lanes: 1 ϭ pre-resin; 2 ϭ unbound; 3 ϭ 50 mM imidazole; 4 ϭ 100 mM EDTA. Fig. 4 . Reduction abrogrates the ability of CTB to bind to the Ni-NTA resin. The intramolecular disulfide bonds in CTB were reduced using 2-mercaptoethanol and then alkylated with iodoacetic acid to prevent reoxidation. The reduced form of CTB was compared with native CTB for its ability to bind to Ni-NTA resin. The position of CTB is indicated by the arrow on the right. Molecular mass markers (in kDa) are shown on the left. Lanes: 1 ϭ reduced, pre-resin; 2 ϭ reduced, unbound; 3 ϭ reduced, 50 mM imidazole; 4 ϭ reduced, 100 mM EDTA; 5 ϭ native, pre-resin; 6 ϭ native, unbound; 7 ϭ native, 50 mM imidazole; 8 ϭ native, 100 mM EDTA.
Asn (N94) and a double mutant consisting of R13 and N94. The modified genes were inserted into the plasmid pMTD107, fused to the OmpA leader peptide and expressed in E.coli strain HMS174(DE3) under control of the IPTG-inducible T7 promoter. The proteins expressed were extensively purified prior to use in the binding studies (data not shown). Each mutant was evaluated for its inability to bind to Ni-NTA using a solid-phase competitive ELISA. Equimolar amounts of each protein were competed against a fixed amount of biotinylated CTB for binding to Ni-NTA coated plates. Figure 5 shows that LT was unable to compete with CT and CTB for binding to Ni 2ϩ ion. Likewise, the R13 mutant was unable to compete. Interestingly, the R94 mutant was still able to compete with biotinylated CTB for binding, but at reduced levels. The R13-N94 double mutant was identical with the R13 mutant in its ability to compete for binding to Ni 2ϩ ion. 
Discussion
For most proteins to bind tightly to the Ni-NTA-Sepharose, there must be a cluster of His residues that will form a coordination complex with the Ni 2ϩ ion. The greater the number of His residues clustered together, the greater is the affinity of the protein for the Ni-NTA-agarose. Amino acids such as Lys, Arg and Trp may also bind to the Ni 2ϩ ion, but not with the affinity associated with His (Hemmasi, 1975; Porath et al., 1975) . As indicated in Figure 1 , the ability to elute CTB from the Ni-NTA resin using imidazole suggested that the binding was being mediated by His residues. The trace amounts of CTA that were observed in the eluate may have been due to incomplete removal of unbound protein, rather than any specific interaction of the protein with the resin. This was confirmed in Figure 5 using a competitive Ni-NTA ELISA, which showed that CTA was unable to compete for binding to the Ni 2ϩ ion.
Despite its significant level of amino acid identity with CT (Dallas and Falkow, 1980) , type I LT-h was unable to bind to Ni 2ϩ ion (Figure 3) . Comparison of the amino acid sequence of each protein revealed that the El Tor strain of CTB used in this study encodes His residues at positions 13, 57 and 94 (Lockman and Kaper, 1983) . The porcine strain of LTB (LTBp) encodes only one His residue, located at position 57 (Dallas and Falkow, 1980) . For this reason, the His at position 57 was not considered to play a critical role in the ability of CTB to bind to Ni 2ϩ ion. We concluded that the other two His residues in CTB, located at positions 13 and 94, may be responsible for the binding. To prove this, these residues were substituted for the amino acids that are encoded by LTB-p (Dallas and Falkow, 1980) . Three mutants were constructed: His13→Arg (R13), His 94→Asn (N94) and an R13-N94 double mutant. These mutants were compared with CTB and LTB for their ability to bind to Ni 2ϩ ion. Figure 5 shows that the R13 substitution completely abolished the ability of CTB to bind to Ni 2ϩ ion, whereas the N94 substitution resulted in a partial loss of binding activity. Hence the affinity of CTB for Ni 2ϩ ion is due primarily to the His residue located at position 13. The reason why these residues are involved in binding to Ni 2ϩ ion is not clear, but it implies that their spatial arrangement is critical for this to occur. Reduction of the intramolecular disulfide bridge within each monomer has been shown previously to affect dramatically the structure and ganglioside binding function of CTB (Ludwig et al., 1985) . As shown in Figure 4 , a similar effect was observed for Ni 2ϩ ion binding in this work, supporting our hypothesis that CTB must be in the proper conformation to interact with the Ni 2ϩ ion.
Although the His residues in CTB are not located contiguous to each other within the linear protein sequence, they are located in the general proximity of the receptor binding cleft of each monomer (Zhang et al., 1995b) . We postulated that these His residues may be clustered sufficiently close to one another spatially to participate in the binding of CTB to Ni 2ϩ ion. To confirm this, the interatomic distance for both the Nδ and Nε atoms was determined for each His residue based on the crystal structure data of CTB (Zhang et al., 1995b) . This information was compared with the interatomic distance for N of 4.2 Å reported for the crystal structure of bis(histidino)-nickel(II) monohydrate (Fraser and Harding, 1967) . Based on this information, none of the His residues are sufficiently close to each other to interact with Ni 2ϩ ion (Table I) . Potential distances between His residues located on adjacent monomers were also examined and were too far away to form a complex with Ni 2ϩ ion (Table I) . Other nearby amino acids that could potentially participate in forming a complex with Ni 2ϩ , such as Lys, Arg and Trp, were also evaluated for their ability to interact with the His residues. Lys91 may be sufficiently close to His94 to form a complex (Lys91Nε-His94Nδ ϭ 10.9 Å; Lys91Nε-His94Nε ϭ 10.0 Å), but none of these other residues appear close enough to form a complex with His13. Clearly, His13 is essential for binding, but we are at a loss to explain why. One possible explanation may be that His13 on one oligomer may form a complex with His13 located on another oligomer. His13 protrudes out from the surface of CTB and could readily interact with free imidazole groups located close to it.
Based on all of the above information, we propose that there are two separate binding sites for each monomer of CTB. His13 is affiliated with one site and requires the participation of a His13 located on a different B subunit. This site is essential for binding, since changes made in His13 completely abrogated binding. In theory, there may be as many as five binding sites per pentameric B subunit. His94 is affiliated with the other site and requires the participation either of Lys91 located on the same monomer or of another residue, such as His94, located on a different pentameric B subunit. Of the two possibilities, we propose the latter. No Ni 2ϩ binding was observed using the R13 mutant, even though the His at position 94 was still intact. Furthermore, only a partial loss of binding activity was observed using the N94 mutant. Formation of the primary complex requires the participation of His13, which anchors the CTB pentamers together tightly enough to permit a secondary complex to form involving His94. This secondary complex is too weak to form on its own and is dependent on the formation of the primary complex. Both of these binding sites would be dependent on the conformation of CTB, which is also consistent with the results of our denaturation study (Figure 4) .
In addition to their difference in Ni 2ϩ binding, CT and LT are also different in the types of glycoconjugate receptors that they recognize (Fukuta et al., 1988) . There are only a few amino acid residues that differ between CTB and the various isolates of LTB, but the residues at positions 13 and 94 are two of them (Dallas and Falkow, 1980; Lockman and Kaper, 1983; Leong et al., 1985; Tsuji et al., 1987) . These two positions have been postulated to be responsible for some of the differences in glycoconjugate binding specificities observed between CT and LT (Sixma et al., 1992a; Merritt et al., 1994) , but their precise role has not been determined experimentally.
We have been unable to ascribe any specific biological function to the ability of CT to bind to Ni 2ϩ ion. The crystal structure of CTB complexed with the GM1-pentasaccharide has been elucidated (Merritt et al., 1994) and indicates that receptor binding is not dependent on the presence of any particular cofactor. Lanthanide binding sites have been identified at the A-B interface of LT (Sixma et al., 1992b) , which suggests that LT may also bind Ca 2ϩ ion. This indirectly suggests that LT may act as a Ca 2ϩ ionophore. The B subunit of CT has previously been shown to possess pharmacological activity (Lebman et al., 1988) and to inhibit mitogen-induced T cell proliferation in vitro (Woogen et al., 1993) . Hence it is possible that the ability of CTB to bind to Ni 2ϩ may be associated with some biological function that we currently do not understand.
In addition to binding to Ni 2ϩ , CTB may be able to bind to other divalent metal cations such as Co 2ϩ , Cd 2ϩ and Zn 2ϩ , as has been observed for other polyhistidine complexes (Fraser et al., 1965) . We have not examined CTB for any of these properties, but it is likely that CTB will also bind to some of these other metal cations. Compared with polyhistidine-tagged proteins, CTB has a relatively low affinity for Ni 2ϩ ion. The protein was eluted from the resin at a concentration of 42 mM imidazole.
Binding to Ni 2ϩ ion may prove useful as an affinity purification method for CTB and complexes composed of CTB. An affinity method has been described for CT previously which employs the GM1 oligosaccharide as the ligand (Tayot et al., 1981) . However, this affinity matrix is not commercially available and the protein must be eluted from the column under extremely acidic conditions. Another method has been described based on the affinity of CT and LT for D-galactose (Uesaka et al., 1994) . Like the Ni-NTA-agarose, this column matrix is commercially available and elution is performed under mild conditions. The method described in this paper provides yet another affinity purification method for CT and CTB which may prove useful in certain applications.
